Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 08, 2020
Champignon Brands has selected Toronto-based Dalriada Drug Discovery Inc.to advance its new chemical entity IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds.